675.3000 -2.65 (-0.39%)
NSE Mar 16, 2026 15:31 PM
Volume: 52,315
 

BOB Capital Markets Ltd.
Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates. EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25
Alembic Pharma has lost -21.90% in the last 3 Months
More from Alembic Pharmaceuticals Ltd.
Recommended